Diabetes drug combos improve HbA1c but increase risks

DRUG combinations for diabetes improve glycaemic control but at the expense of increased risk of adverse events and weight gain, a systematic review shows.

Overall, the cheapest drug, metformin, had the highest benefit to risk profile both as first-line monotherapy and in combination with other drugs, researchers said.

The team, from the Johns Hopkins University School of Medicine, reviewed 166 studies for the US Department of Health.

Metformin plus a sulfonylurea had similar efficacy in reducing HbA1c as the combination of metformin plus a thiazolidinedione, and conferred a lower risk of